Emergent and Johnson & Johnson have a manufacturing agreement for JNJ's (JNJ) - Get Report COVID-19 vaccine.
The vaccine, which received an emergency use authorization from the Food & Drug Administration over the weekend, is now the third vaccine to start being distributed in the United States.
Per a press release from July 2020, "Under the agreement, Emergent will begin providing large-scale drug substance manufacturing for Johnson & Johnson’s adenovirus-based COVID-19 vaccine in 2021, upon successful completion of the activities under the previously executed Technology Transfer Agreement. For the subsequent years beginning 2023, Emergent will provide a flexible capacity deployment model to support additional drug substance batches annually."
https://www.thestreet.com/video/jim-cramer-emergent-bio-buy-jnj-vaccine
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.